Table 2.

Univariate analysis of survival

Prognostic factorsNo. patientsEFSP
Age    
 < 40 53 0.618  
 ≥ 40 12 0.583  
 < 40 vs ≥ 40   .812 
Gender    
 Male 39 0.629  
 Female 26 0.577  
 Male vs female   .959 
Histology    
 NS/LP 58 0.614  
 MC 7 0.571  
 NS/LP vs MC   .714  
Relapse vs refractory    
 Rel 43 0.653  
 Ref 22 0.524  
 Rel vs ref   .051  
 Ref/rel < 1 y 35 0.428  
 Rel > 1 y 30 0.807  
 Ref/rel < 1 y vs rel > 1 y   .001  
Radiation treatment    
 No prior RT 26 0.559  
 Prior RT 39 0.641  
 No prior RT vs prior RT   .756 
B symptoms pre-ICE    
 −B symp 49 0.729  
 +B symp 16 0.225  
 −B symp vs +B symp   < .001  
Extranodal disease pre-ICE    
 +ENS 33 0.818  
 −ENS 32 0.392  
 +ENS vs −ENS   < .001 
Prognostic factorsNo. patientsEFSP
Age    
 < 40 53 0.618  
 ≥ 40 12 0.583  
 < 40 vs ≥ 40   .812 
Gender    
 Male 39 0.629  
 Female 26 0.577  
 Male vs female   .959 
Histology    
 NS/LP 58 0.614  
 MC 7 0.571  
 NS/LP vs MC   .714  
Relapse vs refractory    
 Rel 43 0.653  
 Ref 22 0.524  
 Rel vs ref   .051  
 Ref/rel < 1 y 35 0.428  
 Rel > 1 y 30 0.807  
 Ref/rel < 1 y vs rel > 1 y   .001  
Radiation treatment    
 No prior RT 26 0.559  
 Prior RT 39 0.641  
 No prior RT vs prior RT   .756 
B symptoms pre-ICE    
 −B symp 49 0.729  
 +B symp 16 0.225  
 −B symp vs +B symp   < .001  
Extranodal disease pre-ICE    
 +ENS 33 0.818  
 −ENS 32 0.392  
 +ENS vs −ENS   < .001 

EFS indicates event-free survival; NS/LP, nodular sclerosis/lymphocytic predominance; MC, mixed cellularity; rel, relapse; ref, refractory; RT, radiation treatment; ICE, ifosfamide, carboplatin, and etoposide; symp, symptoms; ENS, extranodal disease.

View Large